NCT03336333 2026-03-09
SEQUOIA
BeOne Medicines
Phase 3 Active not recruiting
Clinical Trials
14 trialsNCT06073821 2026-03-04
Study of Sonrotoclax (BGB-11417) Plus Zanubrutinib (BGB-3111) Compared With Venetoclax Plus Obinutuzumab in Participants With Chronic Lymphocytic Leukemia (CLL)
BeOne Medicines
Phase 3 Active not recruiting
NCT05650723 2026-02-25
Zanubrutinib and Venetoclax as Initial Therapy for Chronic Lymphocytic Leukemia (CLL) With Response-based Obinutuzumab
Weill Medical College of Cornell University
Phase 2 Active not recruiting
NCT06637501 2026-02-23
A Study to Investigate Sonrotoclax Combined With Zanubrutinib Versus Zanubrutinib Alone in Participants With Previously Untreated Chronic Lymphocytic Leukemia
BeOne Medicines
Phase 2 Active not recruiting
NCT04458610 2026-01-13
Zanubrutinib and Rituximab for the Treatment of Previously Untreated Chronic Lymphocytic Leukemia or Small Lymphocytic Lymphoma
M.D. Anderson Cancer Center
Phase 2 Active not recruiting
NCT06441214 2026-01-05
Retrospective-prospective Study to Evaluate Treatment Management and Outcomes of Patients With Waldenström's Macroglobulinemia (WM) Treated in Italy According to the Zanubrutinib (Brukinsa®) Compassionate Use Program (CUP) and in Common Practice Following Commercial Approval.
Fondazione Italiana Linfomi - ETS
Active not recruiting
NCT05952037 2026-01-02
A Study to Investigate Efficacy and Safety of BCL2 Inhibitor Sonrotoclax as Monotherapy and in Combination With Zanubrutinib in Adults With Waldenström Macroglobulinemia
BeOne Medicines
Phase 2 Active not recruiting
NCT06697184 2025-12-17
A Study to Investigate the Safety of Novel Dose Ramp-up Schedule(s) When Initiating Sonrotoclax in Participants Treated for Blood Cancers.
BeOne Medicines
Phase 1/2 Active not recruiting
NCT05718869 2025-11-04
Tafasitamab and Zanubrutinib for the Treatment of Patients With Newly Diagnosed Chronic Lymphocytic Leukemia or Small Lymphocytic Lymphoma, TaZA CLL Study
City of Hope Medical Center
Phase 2 Active not recruiting
NCT04170283 2025-10-21
Long-term Extension Study of Zanubrutinib (BGB-3111) Regimens in Participants With B-cell Malignancies
BeOne Medicines
Phase 3 Active not recruiting
NCT04002297 2025-09-26
MANGROVE
BeiGene
Phase 3 Active not recruiting
NCT04515238 2025-06-10
CLL2-BZAG
German CLL Study Group
Phase 2 Active not recruiting
NCT04662255 2025-05-28
BRUIN-MCL-321
Eli Lilly and Company
Phase 3 Active not recruiting
NCT04460248 2025-05-02
Zanubrutinib, Lenalidomide and Rituximab (ZR2) in Elderly Treatment-naive Patients With Diffuse Large B-cell Lymphoma (DLBCL)
Ruijin Hospital
Phase 2 Active not recruiting